tetano
Editor, Senior Moderator
Cureus
. 2023 May 25;15(5):e39506.
doi: 10.7759/cureus.39506. eCollection 2023 May. Myasthenia Gravis Associated With COVID-19 Infection
Waleed Sadiq[SUP] 1 [/SUP], Madeeha Subhan Waleed[SUP] 2 [/SUP], Taqi A Rizvi[SUP] 3 [/SUP], Shahkar Khan[SUP] 3 [/SUP], Halim El Hage[SUP] 1 [/SUP]
Affiliations
COVID-19 first emerged in Wuhan, China in late December 2019. The disease majorly involves the lungs leading to various respiratory complications; however, neurological manifestations of the disease are also described in the literature. Here, we report a case of COVID-19-induced seronegative myasthenia gravis (MG). We discuss the cases of COVID-19 and MG already described in the literature in regard to their presentation and serological findings to better understand the association between the two disease processes. MG may be missed in patients after COVID-19 infections because of the comorbidities and anti-acetylcholine receptor and anti-muscle-specific tyrosine kinase antibodies being negative. Evidence from more studies will help analyze the pathological timeline of the disease process and the immunological characteristics of COVID-19-induced MG which can prove to have morbidity and mortality benefit in patients with COVID-19-induced MG.
Keywords: autoimmune; coronavirus; coronavirus disease; covid-19; myasthenia gravis (mg); sars; sars-cov-2.
. 2023 May 25;15(5):e39506.
doi: 10.7759/cureus.39506. eCollection 2023 May. Myasthenia Gravis Associated With COVID-19 Infection
Waleed Sadiq[SUP] 1 [/SUP], Madeeha Subhan Waleed[SUP] 2 [/SUP], Taqi A Rizvi[SUP] 3 [/SUP], Shahkar Khan[SUP] 3 [/SUP], Halim El Hage[SUP] 1 [/SUP]
Affiliations
- PMID: 37366447
- PMCID: PMC10290576
- DOI: 10.7759/cureus.39506
COVID-19 first emerged in Wuhan, China in late December 2019. The disease majorly involves the lungs leading to various respiratory complications; however, neurological manifestations of the disease are also described in the literature. Here, we report a case of COVID-19-induced seronegative myasthenia gravis (MG). We discuss the cases of COVID-19 and MG already described in the literature in regard to their presentation and serological findings to better understand the association between the two disease processes. MG may be missed in patients after COVID-19 infections because of the comorbidities and anti-acetylcholine receptor and anti-muscle-specific tyrosine kinase antibodies being negative. Evidence from more studies will help analyze the pathological timeline of the disease process and the immunological characteristics of COVID-19-induced MG which can prove to have morbidity and mortality benefit in patients with COVID-19-induced MG.
Keywords: autoimmune; coronavirus; coronavirus disease; covid-19; myasthenia gravis (mg); sars; sars-cov-2.